Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Operations (2019 - 2025)

Historic Cash from Operations for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $142.2 million.

  • IDEAYA Biosciences' Cash from Operations rose 38885.32% to $142.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.3 million, marking a year-over-year increase of 3168.16%. This contributed to the annual value of -$247.6 million for FY2024, which is 11487.19% down from last year.
  • Latest data reveals that IDEAYA Biosciences reported Cash from Operations of $142.2 million as of Q3 2025, which was up 38885.32% from -$62.5 million recorded in Q2 2025.
  • IDEAYA Biosciences' Cash from Operations' 5-year high stood at $142.2 million during Q3 2025, with a 5-year trough of -$121.7 million in Q4 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$24.2 million (2022), whereas its average is -$25.6 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Cash from Operations plummeted by 41227.47% in 2024, and later skyrocketed by 38885.32% in 2025.
  • Over the past 5 years, IDEAYA Biosciences' Cash from Operations (Quarter) stood at -$16.7 million in 2021, then plummeted by 40.3% to -$23.4 million in 2022, then fell by 1.62% to -$23.7 million in 2023, then tumbled by 412.27% to -$121.7 million in 2024, then soared by 216.9% to $142.2 million in 2025.
  • Its last three reported values are $142.2 million in Q3 2025, -$62.5 million for Q2 2025, and -$60.3 million during Q1 2025.